Ranibizumab (Lucentis) Intravitreal Injection from Japan
Ranibizumab is a humanized monoclonal antibody fragment for wet AMD. Classified HTS 3002.15.00.11 as immunological VEGF inhibitor in measured doses.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Pharmaceuticals: patented pharma from JP/EU/KR/CH/LI — 15% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Ophthalmic sterile requirements; declare intravitreal use